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Abstract
QuantiFERON®-TB Gold in-tube (QFT-GIT) supernatants may be important samples for
use in assessment of anti-tuberculosis (TB) antibodies when only limited volumes of blood
can be collected and when a combination of antibody and cytokine measurements are
required. These analytes, when used together, may also have the potential to differentiate
active pulmonary TB (APTB) from latent TB infection (LTBI). However, few studies have
explored the use of QFT-GIT supernatants for investigations of antibody responses. This
study determined the correlation and agreement between anti-CFP-10 and anti-ESAT-6
antibody concentrations in QFT-GIT nil supernatant and serum pairs from 68 TB household
contacts. We also explored the ability of Mycobacterium tuberculosis (M.tb) specific antibod-
ies, or ratios of antibody to interferon gamma (IFN-γ) in QFT-GIT supernatants, to differenti-
ate 97 APTB cases from 58 individuals with LTBI. Sputum smear microscopy was used to
define APTB, whereas the QFT-GIT and tuberculin skin test were used to define LTBI.
There were strong and statistically significant correlations between anti-CFP-10 and anti-
ESAT-6 antibodies in unstimulated QFT-GIT supernatants and sera (r = 0.89; p<0.0001 for
both), and no significant differences in antibody concentration between them. Anti-CFP-10
& anti-ESAT-6 antibodies differentiated APTB from LTBI with sensitivities of 88.7% & 71.1%
and specificities of 41.4% & 51.7% respectively. Anti-CFP-10 antibody/M.tb specific IFN-γ
and anti-ESAT-6 antibody/M.tb specific IFN-γ ratios had sensitivities of 48.5% & 54.6% and
specificities of 89.7% and 75.9% respectively. We conclude that QFT-GIT nil supernatants
may be used in the place of sera when measuring antibody responses, reducing blood vol-
umes needed for such investigations. Antibodies in QFT-GIT nil supernatants on their own
discriminate APTB from LTBI with high sensitivity but have poor specificity, whereas the
reverse is true when antibodies are used in combination with M.tb specific cytokines. Further
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antibody and antibody/cytokine combinations need to be explored to achieve better diag-
nostic accuracy.
1.0 Introduction
Almost a quarter the world’s population is estimated to be infected with Mycobacterium tuber-
culosis (M.tb), the bacterium that causes tuberculosis (TB) [1]. The QuantiFERON1-TB Gold
in-tube (QFT-GIT) test is an immunological assay that diagnoses M.tb infection by detecting
M.tb specific interferon-gamma (IFN-γ) in whole blood culture supernatants [2]. It is able to
do so with a high sensitivity but cannot differentiate latent TB infection (LTBI) from active TB
disease [3]. In the assay, whole blood is stimulated with the freeze dried antigens, early secre-
tory target (ESAT)-6, culture filtrate protein (CFP)-10 and TB7.7, to elicit M.tb specific
responses. The assay also includes positive (mitogen) controls where whole blood is stimulated
with phytohaemagglutinin (PHA), a T cell mitogen, and negative (nil) controls where whole
blood is left unstimulated [4]. We propose that after completion of QFT-GIT assays, culture
supernatants may still be a valuable resource for the reliable measurement of antibody
responses.
Several studies have reported the use of QFT-GIT supernatants for extended cytokine
profiling [5–8] but we could only find one that has used these samples for antibody analy-
sis [9]. There is increasing evidence supporting a role for antibody mediated immunity
against TB [10,11], and so it is becoming important to look at levels of circulating anti-
bodies in TB patients and their contacts. Furthermore, since antibodies are increased in
individuals with active pulmonary TB (APTB) in comparison to those with LTBI they
may have the potential to differentiate the two M.tb infection states [12]. This is particu-
larly important because biomarkers that can distinguish APTB from LTBI may have value
as predictors of progression to TB disease. QFT-GIT supernatants may provide an impor-
tant sample in studies measuring antibody responses for this purpose, in instances where
serum or plasma is not routinely available or is in limited quantity. This could be the case
in TB studies involving young children from whom limited blood can be obtained, or
latent TB diagnostic studies that had not originally set out to look at antibody responses
in their study populations.
The concentrations of circulating antibodies in vivo are normally investigated by testing
serum or plasma. However, it remains unknown whether the concentrations of antibodies in
QFT-GIT supernatants are also representative of circulating antibody. Since QFT-GIT super-
natants are obtained from 16–24 h whole blood cultures it is possible that this period of culture
could be sufficient for the production of antibodies into supernatant by antibody secreting
cells that may be present in circulation [13,14]. Additionally, stimulation by antigens in test or
mitogen control tubes could lead to the differentiation of memory B cells into antibody secret-
ing cells [15,16], leading to a higher concentration of antibodies in QFT-GIT supernatants
compared to sera. We investigated whether the concentrations of anti-mycobacterial IgG anti-
bodies from QFT-GIT nil supernatants and sera were different. Additionally, QFT-GIT nil
and mitogen supernatant antibody concentrations were compared to determine the impact of
a highly potent cell stimulant such as PHA on antibody levels. We also used these data to evalu-
ate the ability of antibodies in QFT-GIT supernatants to detect APTB disease independently,
or in combination with IFN-γ cytokine data, in a study group of APTB cases and individuals
with LTBI.
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2.0 Materials and methods
2.1 Study design and participants
This study was of a cross-sectional design and was nested in a larger TB household contact
research project based in Kampala, Uganda that set out to determine whether co-infections
among household contacts (HHCs) of active pulmonary TB (APTB) cases increased their sus-
ceptibility to infection with M.tb [17]. APTB cases and their HHCs were recruited from Kise-
nyi & Kitebi municipalities of Kampala district between May 2011 and January 2012. APTB
was defined based on a positive result following acid-fast bacilli sputum smear microscopy.
APTB cases were only selected if they were above the age of 18 years and had just began anti-
TB treatment or had received treatment for less than a month. The HHCs were selected if they
lived or shared meals with the APTB cases for two weeks prior to their diagnosis with TB, with-
out any bias towards age or gender. The QFT-GIT test was used in conjunction with the tuber-
culin skin test (TST) to determine M.tb infection among HHCs with no signs or symptoms of
TB, with those who were positive on both tests classified as having a latent TB infection
(LTBI), and those who tested negative on both tests classified as uninfected.
2.2 Samples
Blood was drawn for serum isolation for diagnosis of co-infections and QFT-GIT testing for
M.tb infection, concurrently. We had access to stored paired serum and QFT-GIT nil superna-
tants from 68 HHCs left over from these investigations, and used them to determine correla-
tion and agreement between antibody concentrations in these two sample types. We also had
access to paired QFT-GIT nil and mitogen supernatants from 63 uninfected individuals, 58
individuals with LTBI and 97 APTB cases. We used these samples to determine whether anti-
body concentrations between samples correlated and agreed well with each other, and whether
they could be employed as biomarkers to differentiate APTB from LTBI. This research was
exploratory. All individuals were selected based upon availability of sample and information
on TB infection status.
2.3 Ethical approvals
This study was approved by the Makerere University Higher Degrees Research & Ethics Com-
mittee and the Uganda National Council for Science & Technology. All individuals provided
informed written consent and they also consented to the use of their samples for future immu-
nological analyses. All samples were fully anonymised before laboratory investigations to pro-
tect the study participants’ identities.
2.4 Antigens
We used CFP-10 and ESAT-6 of M.tb (BEI Resources, National Institute of Allergy and Infec-
tious Diseases, National Institutes of Health) for antibody assays. These proteins were chosen
because they are encoded by genes in the region of difference (RD)-1 which is present in M.tb
but absent in Mycobacterium bovis Bacille-Calmette-Gue´rin (BCG) as well as most environ-
mental mycobacteria [18]. Immune responses to these proteins are therefore valuable as bio-
markers of M.tb infection.
2.5 Antibody ELISA assay
In the procedure, 96 well Immulon1 4 HBX microtitre plates (Thermo Scientific, USA) were
coated using 50 μl/well of 2.5 μg/ml CFP-10 or ESAT-6 diluted in bicarbonate coating buffer
overnight at 4˚C. We also coated the plates with eight, two-fold serial dilutions of human IgG
Use of QuantiFERON®-TB Gold in-tube supernatants to measure antibodies
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reference standard (Genscript) starting at a concentration of 250 ng/ml. The plates were then
washed three times with phosphate saline buffer containing 0.05% tween 20 (PBST) and then
blocked with 150 μl/well of 1% skimmed milk for 2 h. A 50 μl volume of serum or supernatant
diluted 1:100 in PBST was then added to antigen-coated wells in duplicate while PBST was
added to IgG coated wells. Serum-supernatant pairs were run on the same plate and plates
were incubated overnight at 4˚C. The plates were washed four times in PBST and then 50 μl/
well of polyclonal rabbit anti-human IgG conjugated with horseradish peroxidase (Dako, DE)
at 0.5 μg/ml in PBST was added to each well and incubated for 1 h at room temperature. The
plates were then washed as before and then 50 μl/well of 3,3’,5,5’-tetramethylbenzidine (BD
Biosciences-US) was added and the plates developed for 15 min. The optical density (OD) was
measured at a wavelength of 450 nm and 630 nm filter as a reference using an ELISA plate
reader (Biotek). Human IgG standard concentrations were then used to generate specific anti-
body concentrations. A pooled sample of QFT-GIT nil supernatants from active TB cases was
used as a positive control on each plate. ELISA plate results were only considered to be valid
when the positive control antibody concentration was within 3 standard deviations of the
mean of the positive control values from all the plate runs.
2.6 Data analysis
Data was analysed using Stata release 12.0 statistical package (Statacorp LP, College Station,
TX, USA) and GraphPad Prism software, version 6.01 (GraphPad Inc., San Diego, CA, USA).
We used Spearman rank correlation to test for associations between the antibody concentra-
tions obtained from assaying paired QFT-GIT supernatants and sera. We used Bland Altman
plots [19] to see if there were any differences between log transformed antibody concentrations
obtained from sample pairs [20]. For the biomarker analyses, we used the Wilcoxon rank sum
test to compare antibody responses or antibody/IFN-γ ratios between groups. We then used
receiver operating characteristic (ROC) curves to evaluate ability of these measurements to dis-
criminate APTB cases from the individuals with LTBI. Youden’s index, a measure that pro-
vides equal consideration to specificity and sensitivity which is defined as the maximum value
of sensitivity + specificity– 1 [21], was used to select optimal antibody or antibody/IFN-γ ratio
cut-off levels for positivity from ROC curve analyses.
3.0 Results
3.1 Demographic characteristics
The median age of the household contacts used for QFT-GIT nil supernatant versus serum
comparisons was 14 years (range: 1–66), 44/68 (64.71%) were female, 30/68 (44.1%) were
LTBI positive and 6/68 (8.8%) were HIV positive. Characteristics of uninfected controls, indi-
viduals with LTBI & APTB cases used for QFT-GIT nil versus QFT-GIT mitogen comparisons
and biomarker analyses are described in Table 1. Individuals with APTB & LTBI were older
than the uninfected controls but there were no differences in socioeconomic status across the
three groups. As expected, there was a higher proportion of males (55.7%; 54/97) and HIV
sero-positive individuals (39.2%; 38/97) in the APTB group compared to the LTBI and unin-
fected control groups [22,23].
3.2 Agreement between QFT-GIT nil supernatant versus serum and
QFT-GIT mitogen versus nil supernatant antibody concentrations
We compared the concentration of anti-mycobacterial antibodies in paired QFT-GIT nil
supernatants and sera from the TB household contacts to determine whether there were
Use of QuantiFERON®-TB Gold in-tube supernatants to measure antibodies
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differences between the two. There were strong and statistically significant correlations
between anti-CFP-10 and anti-ESAT-6 antibody concentrations obtained from assaying
QFT-GIT nil supernatants and serum (Fig 1A). In order to assess if this observation was due to
agreement between the antibody results from these two samples and was not simply a result of
an association, we constructed Bland Altman plots and determined the mean difference in
antibody concentrations obtained from assaying QFT-GIT nil supernatants versus serum and
its confidence intervals. We found that the mean difference in antibody concentrations
obtained from assaying QFT-GIT nil supernatants versus serum was 0.014 (95% CI = -0.388,
0. 416) for anti-CFP-10 antibodies and 0.003 (95% CI = -0.272, 0.278) for anti-ESAT-6 anti-
bodies (Fig 1B). This result implied that there was no evidence of a systematic bias or differ-
ence in antibody concentration between the serum and QFT nil supernatant samples and that
there is therefore agreement between antibody measurements from the two sample types.
Supernatants from QFT-GIT stimulated tubes could also have value for antibody analyses.
In order to investigate this, paired QFT-GIT mitogen and nil supernatants from uninfected
individuals, those with LTBI and APTB cases were tested for antibodies against CFP-10 and
ESAT-6 and antibody concentrations from the two sample types compared. There were strong
and statistically significant correlations between antibody concentrations from QFT-GIT
mitogen and nil supernatants in the individual groups (S1 Fig). Bland Altman analysis showed
no evidence of differences between these two QFT-GIT supernatants regardless of the TB
infection status of the study participants (S2 Fig). We combined the data from the uninfected
individuals, those with LTBI and APTB cases and calculated the overall correlation and agree-
ment. The correlation remained strong and statistically significant (Fig 2A) and Bland Altman
analyses continued to show no significant difference: the mean difference in antibody concen-
trations obtained from assaying QFT-GIT mitogen versus nil supernatants was -0.006 (95% CI
= -0.268, 0.257) for anti-CFP-10 antibodies and 0.011 (95% CI = - 0.178, 0.199) for anti-ESAT-
6 antibodies (Fig 2B). This meant there was also agreement between QFT-GIT mitogen and
nil supernatants antibody concentrations.
3.3 Using antibodies in QFT-GIT supernatants to differentiate APTB
from LTBI
Antibodies in QFT-GIT supernatants may have use as biomarkers for the detection of TB dis-
ease among M.tb infected individuals. We therefore determined whether anti-CFP-10 and
anti-ESAT-6 antibodies could discriminate APTB cases from individuals with LTBI. In order
to investigate this, we used data obtained from testing QFT-GIT nil supernatants from the
individuals with LTBI and APTB. APTB cases had higher concentrations of anti-CFP-10 and
anti-ESAT-6 antibodies compared to individuals with LTBI (Fig 3A). We found that anti-
CFP-10 & anti-ESAT-6 antibodies were able to differentiate APTB from LTBI with an area
under the curve of 0.67 (95% CI: 0.58–0.76) & 0.63 (95% CI: 0.54–0.72) respectively (Fig 3B).
Table 1. Study participant characteristics.
Characteristic Uninfected (n = 63) LTBI (n = 58) APTB (n = 97) Total (n = 218)
Mean age & range (years) 13 (1, 66) 23 (1, 66) 29 (18, 53) 23 (1, 66)
Females 39 (61.9%) 38 (65.5%) 43 (44.3%) 120 (55.1%)
HIV positive 3 (4.8%) 5 (8.6%) 38 (39.2%) 46 (21.1%)
Low SES a 28 (45.2%) 28 (48.3%) 54 (62.8%) 110 (53.4%)
LTBI = latent tuberculosis infection, SES = socioeconomic status, and APTB = active pulmonary tuberculosis
a Individuals were either of low or medium SES
https://doi.org/10.1371/journal.pone.0188396.t001
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As mentioned previously, we used Youden’s index to identify the optimal antibody cut-offs for
positivity from the ROC curve analyses. This measure gives equal consideration to the values
of sensitivity and specificity [21]. Using the cut-offs selected, anti-CFP-10 antibodies differen-
tiated APTB from LTBI with a sensitivity of 87.6% (95% CI: 79.4–93.4) and had a diagnostic
specificity of 41.4% (95% CI: 28.6–55.1), whereas anti-ESAT-6 antibodies had a sensitivity of
71.1% (95% CI: 61.0–79.9) and a specificity of 51.7% (95% CI: 38.2–65.0) as shown in Table 2.
These findings, taken together, with the area under ROC curve and Youden’s index values
indicate that antibodies against CFP-10 differentiated APTB cases from individuals with LTBI
with better accuracy compared to antibodies against ESAT-6.
Fig 1. Anti-CFP (culture filtrate protein)-10 & anti-ESAT (early secretory antigenic target)-6 antibody concentrations in QFT-GIT
(QuantiFERON®-TB Gold in tube-test) nil control supernatants strongly correlate with those in paired sera and there are no statistical
differences between them. Panel A: scatter plots showing correlation. The coefficient (r) and the p values shown correspond to results from
Spearman’s rank correlation. The solid lines are lines of identity. Panel B: Bland Altman plots showing agreement. The solid horizontal line represents
the bias or average difference while the dotted horizontal lines are 95% confidence intervals.
https://doi.org/10.1371/journal.pone.0188396.g001
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3.4 Using QFT-GIT supernatant antibody/IFN-γ ratio to differentiate
APTB from LTBI
Analysis of QFT-GIT M.tb specific IFN-γ data generated from the study participants showed
that there were higher levels in LTBI compared to APTB (S3 Fig) while our antibody results
showed the reverse (Fig 3A). We therefore explored whether antibody/IFN-γ ratio could better
discriminate the two groups. We found that these ratios were significantly higher among
APTB cases compared to individuals with LTBI (Fig 4A) and so evaluated their diagnostic
potential. ROC curve analysis showed that anti-CFP-10 & anti-ESAT-6 antibody/IFN-γ ratios
were able to differentiate APTB from LTBI with an area under the curve of 0.74 (95% CI: 0.66–
0.82) & 0.70 (95% CI: 0.61–0.78) respectively (Fig 4B). Optimal cut-offs determined from
Fig 2. Anti-CFP (culture filtrate protein)-10 & anti-ESAT (early secretory antigenic target)-6 antibody concentrations in QFT-GIT mitogen
control supernatants strongly correlate with those in QFT-GIT nil control supernatants and there are no statistical differences between
them. Panel A: scatter plots showing correlation. The coefficient (r) and the p values shown correspond to results from Spearman’s rank correlation.
The solid lines are lines of identity. Panel B: Bland Altman plots showing agreement. The solid horizontal line represents the bias or average difference
while the dotted horizontal lines are 95% confidence intervals.
https://doi.org/10.1371/journal.pone.0188396.g002
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Youden’s index values showed that anti-CFP-10 antibody/IFN-γ ratios had a sensitivity of
48.5% (95% CI: 38.2–58.8) and a specificity of 89.7% (95% CI: 78.8–96.1), whereas anti-ESAT-
6 antibody/IFN-γ ratios had a sensitivity of 54.6% (95% CI: 44.2–64.8) and a specificity of
75.9% (95% CI: 62.8–86.1) as shown in Table 3. This data shows that although the overall diag-
nostic potential as shown by area under ROC curve and specificity were improved when anti-
body/IFN-γ ratios were used to differentiate APTB from LTBI, the sensitivities of both
biomarkers were significantly reduced.
Fig 3. CFP-10 and ESAT-6 specific antibodies in QFT-GIT nil control supernatants from APTB cases & individuals with LTBI and their
discriminatory potential. Panel A: box and whisker plots showing differences in antibodies between the two groups. Panel B: Receiver operator
characteristic curves showing discriminatory potential at different antibody cut-offs.
https://doi.org/10.1371/journal.pone.0188396.g003
Table 2. Potential of anti-CFP-10, anti-ESAT-6 antibodies to differentiate active and latent TB infection.
Biomarker Cut-off % Sensitivity (95% CI) % Specificity (95% CI) Youden’s index (%)
Anti-CFP-10 antibodies 998.6 ng/ml 87.6 (79.4–93.4) 41.4 (28.6–55.1) 30
Anti-ESAT-6 antibodies 1314.4 ng/ml 71.1 (61.0–79.9) 51.7 (38.2–65.0) 22.9
https://doi.org/10.1371/journal.pone.0188396.t002
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4.0 Discussion
This data showed that there is good correlation and agreement between antibody concentra-
tions in QFT-GIT supernatants and sera from TB household contacts for both anti-CFP-10 &
anti-ESAT-6 antibodies. The study also demonstrated good correlation and agreement
between antibody concentrations in QFT-GIT nil and mitogen supernatants. It showed that
anti-CFP-10 & anti-ESAT-6 antibodies in QFT-GIT supernatants when used independently
detect TB disease in M.tb infected individuals with high sensitivity but have poor specificity
Fig 4. Anti-CFP-10 and anti-ESAT-6 antibody/IFN-γ ratios in APTB cases & individuals with LTBI and their discriminatory potential. Panel A:
box and whisker plots showing differences in antibody/IFN-γ ratio between the two groups. The Wilcoxon rank-sum test was used for comparisons. Panel B:
Receiver operator characteristic curves showing discriminatory potential at different antibody/IFN-γ ratio cut-offs.
https://doi.org/10.1371/journal.pone.0188396.g004
Table 3. Potential of anti-CFP-10 and anti-ESAT-6 antibody/IFN-γ ratios to differentiate active and latent TB infection.
Biomarker Cut-off % Sensitivity (95% CI) % Specificity (95% CI) Youden’s index (%)
Anti-CFP-10 antibody/IFN-γ ratio 512.0 48.5 (38.2–58.8) 89.7 (78.8–96.1) 38.1
Anti-ESAT-6 antibody/IFN-γ ratio 292.8 54.6 (44.2–64.8) 75.9 (62.8–86.1) 30.5
https://doi.org/10.1371/journal.pone.0188396.t003
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and the reverse is true when these antibodies are used in combination with IFN-γ cytokine
measurements.
The lack of any significant differences in concentrations of antibodies between sera and
QFT-GIT nil supernatants, together with the strong correlation observed, suggests that serum
anti-mycobacterial antibody concentrations can be approximated by QFT-GIT nil supernatant
values in the TB household contacts studied. This finding was reassuring because we initially
thought that there could be some differences as a result of accumulation of antibodies pro-
duced by Mycobacterium specific antibody secreting cells over the 16–24 h period of culture
necessary for the QFT-GIT assays. However, we found no evidence of this effect. The reasons
for agreement between serum and QFT-GIT supernatant antibody values may be because the
QFT-GIT culture period is too short to allow accumulation of appreciable amounts of antibod-
ies in the supernatants. It is important to mention however that the study participants used for
these analyses were all healthy HHCs with no signs or symptoms of active TB. This result may
therefore reflect the low levels of circulating antibody secreting cells in individuals without an
active infection [24]. Studies measuring antibodies in lymphocyte supernatant assays suggest
that there are higher levels of anti-mycobacterial antibodies following culture of cells from
active TB cases [14]. However, we were not able to access matched serum and QFT-GIT super-
natant pairs from active TB cases to investigate this effect in whole blood culture supernatants.
This was because the parent study did not include collection of sera from APTB cases in its
protocol, and is a limitation of our study. Our observation of agreement between QFT-GIT
supernatant and serum antibody concentrations may therefore be limited to individuals with-
out active disease, but is nevertheless an important finding.
There were strong and statistically significant correlations between anti-mycobacterial anti-
body concentrations in QFT-GIT nil and mitogen supernatants from our study group of unin-
fected individuals, those with LTBI and APTB cases. Further analysis showed no significant
differences in antibody concentrations between these samples, indicating a good agreement.
This implies that even highly potent cell stimulants such as PHA in QFT-GIT mitogen tubes
may not have any significant effect on antibody levels over the 16–24 h period of culture. Fur-
thermore, the lack of this effect seems to extend to the majority of the individuals studied,
regardless of their TB infections status. This finding highlights the possibility of using
QFT-GIT nil and mitogen supernatants interchangeably for antibody analyses.
Our study showed that concentrations of antibodies in QFT-GIT supernatants differed
between individuals with APTB from LTBI. The observation of higher anti-CFP-10 and anti-
ESAT-6 antibodies in APTB cases compared to individuals with LTBI is in keeping with prior
findings from other studies [12,25,26]. Anti-CFP-10 antibodies differentiated APTB cases
from individuals with LTBI with high sensitivity (~89%). This value was higher than that
reported in a meta-analysis of the performance of purified M.tb antigens, including CFP-10,
for the sero-diagnosis of TB [27]. Anti-ESAT-6 antibodies distinguished the two groups with a
sensitivity of 71%. This was slightly higher than that reported in a study in The Gambia evalu-
ating anti-ESAT-6 antibodies for sero-diagnosis [28]. However, the diagnostic specificity of
both anti-CFP-10 and anti-ESAT-6 antibodies was low. The individuals with LTBI may have
developed antibodies against the M.tb proteins assessed, resulting in a higher number of false
positives and a decrease in the overall specificity. However, it is also important to note that
individuals with LTBI are not a completely homogenous population. Results from positron
emission tomography—computed tomography (PET-CT) scans indicate that this group may
contain individuals at various stages of TB reactivation even in the absence of clinical symp-
toms of disease [29]. As expected, M.tb specific IFN-γ concentrations were higher in individu-
als with LTBI compared to those with APTB [30], a reverse of what was seen with the
antibodies. We therefore explored antibody cytokine combinations in the form of M.tb specific
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antibody/IFN-γ ratios for use in the differentiation of APTB cases from individuals with LTBI.
We showed that anti-CFP-10/IFN-γ ratio and anti-ESAT-6/IFN-γ ratios differed between the
two groups and distinguished them with a high specificity (>75%). However, this approach
resulted in a substantial decrease in sensitivity compared to when antibodies were used
independently.
Our investigation of QFT-GIT supernatant antibodies and combinations of antibody &
cytokine data as TB biomarkers was limited to only anti-CFP-10, anti-ESAT antibodies and
IFN-γ. Study of more QFT-GIT supernatant antibody or antibody cytokine combinations may
identify immunological markers capable of distinguishing APTB from LTBI with both high
sensitivity and specificity. Such approaches have shown promise in the diagnosis of leprosy. A
study by van Hooij et al. using lateral flow assays to detect cytokines and antibodies in whole
blood culture supernatants showed that together these biomarkers helped distinguish leproma-
tous from tuberculoid forms of the disease [31]. Our data showing good correlation and agree-
ment between antibody concentration in sera and QFN-GIT supernatants is an important
finding because it means this approach can be used to assess both humoral and cellular
responses, thereby reducing blood volumes.
In conclusion, our study shows that QFT-GIT supernatants can be used to substitute sera
during the study of anti-TB antibody immunity in HHC of APTB cases. It shows that there is
no effect of PHA stimulation in QFT-GIT whole blood cultures on antibody concentrations.
Lastly, the study shows that anti-CFP-10 & anti-ESAT-6 antibodies in QFT-GIT supernatants
differentiate APTB from LTBI with high sensitivity but have poor diagnostic specificity. The
reverse is true when ratios of these antibodies and QFT-GIT IFN-γ cytokine measurements
are used. More antibody or antibody/cytokine combinations need to be investigated to dis-
cover those with the best discriminatory power.
Supporting information
S1 Fig. Antibody concentrations in QFT-GIT nil control supernatants strongly correlate
with those in QFT-GIT mitogen control supernatants regardless of TB infection. Panel A:
anti-CFP-10 antibodies. Panel B: anti-ESAT-6 antibodies. The correlation coefficient (r) and
the p values shown correspond to results from Spearman’s rank correlation.
(TIFF)
S2 Fig. Bland Altman plots show no statistical differences in antibody concentrations
between QFT-GIT nil and QFT-GIT mitogen control supernatants regardless of TB infec-
tion. The solid horizontal line represents the bias or average difference while the dotted hori-
zontal lines are 95% confidence intervals. Panel A: anti-CFP-10 antibodies. Panel B: anti-
ESAT-6 antibodies.
(TIFF)
S3 Fig. Individuals with LTBI have higher concentrations of IFN-γ compared to APTB
cases. Panel A: anti-CFP-10 antibody/IFN-γ ratio. Panel B: anti-ESAT-6 antibody/IFN-γ ratio.
The Wilcoxon rank-sum test was used for comparisons.
(TIFF)
S1 Dataset. QFT-GIT nil supernatant Vs. serum comparisons.
(XLSX)
S2 Dataset. QFT-GIT mitogen Vs. nil comparisons.
(XLSX)
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